BCAL Secures Funding for FY2027 Update
Filed with ASX · · 4 pages · English
Summary by 6ix AI
BCAL Diagnostics Limited has announced an update regarding its funding for the upcoming fiscal year, detailing the establishment of a Convertible Note Facility. The company has raised a portion of the facility through the issuance of convertible notes and outlines the terms and conditions associated with these notes. Further drawdowns of the notes will require shareholder approval to avoid impacting the company's listing capacity. The announcement includes a summary of the convertible note terms and the intended use of the funds raised.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
BCAL Diagnostics Limited on 6ix
Story so far
Earlier from BCAL Diagnostics
- BCAL to Acquire Shares in Genetic Signatures
- BCAL Secures Funding for FY2027
- BCAL Develops New Blood Test for Breast Cancer Recurrence
- BCAL Launches Early Detection Cancer Platform
- BCAL Appoints Anne-Louise Arnett as Chief Executive Officer
Later from BCAL Diagnostics
- BCAL Takes Interest in Genetic Signatures to 18.46%
- Appendix 4E and Annual Report to shareholders
- BCAL Introduces Avantect Multi-Cancer Early Detection Test
- BREASTESTplus 2 clinically validated
- GSS: Response to Media Speculation & BCAL letter to GSS
Follow BCAL Diagnostics into a list and get an email when it puts out news.
Follow BCAL Diagnostics